Infective Endocarditis
3
Pipeline Programs
2
Companies
3
Clinical Trials
2
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
3
Early DiscoveryClinical DevelopmentMarket
On Market (2)
Approved therapies currently available
U
CUBICINApproved
daptomycin
Unknown Companyintravenous2003
U
CUBICIN RFApproved
daptomycin
Unknown Companyintravenous2003
Competitive Landscape
2 companies ranked by most advanced pipeline stage
M&
CytoSorbentsPRINCETON, NJ
2 programsCytoSorbN/A1 trial
hemoadsorber for removal of cytokinesN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Merck & Co.daptomycin
CytoSorbentsCytoSorb
CytoSorbentshemoadsorber for removal of cytokines
Clinical Trials (3)
Total enrollment: 332 patients across 3 trials
Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
Start: Feb 2009Est. completion: Nov 201124 patients
Phase 4Terminated
Does Whole Blood Adsorber During CPB Reduce Vasoactive Drugs Postoperatively in Endocarditis Patients Undergoing Valve Surgery?
Start: May 2019Est. completion: Dec 202020 patients
N/ACompleted
Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients With Infective Endocarditis
Start: Jan 2018Est. completion: Dec 2020288 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space